| [1] |
Jang SY. Traumatic Optic Neuropathy[J]. Korean J Neurotrauma, 2018, 14(1): 1－5.
|
| [2] |
Singman EL, Daphalapurkar N, White H, et al. Indirect traumatic optic neuropathy[J]. Mil Med Res, 2016, 11, 3: 2.
|
| [3] |
Kumaran AM, Sundar G, Chye LT. Traumatic optic neuropathy: a review[J]. Craniomaxillofac Trauma Reconstr, 2015, 8(1): 31－41.
|
| [4] |
邹伟，陈吉钢，张丹枫，等. The Progress of Treatment of Traumatic Optic Neuropathy[J]. 现代生物医学进展，2016，16(16))：3176－3179.
|
| [5] |
Wladis EJ, Aakalu VK, Sobel RK, et al. Interventions for Indirect Traumatic Optic Neuropathy: A Report by the American Academy of Ophthalmology[J]. Ophthalmology, 2021, 128(6): 928－937.
|
| [6] |
Levin LA, Beck RW, Joseph MP, et al. The treatment of traumatic optic neuropathy: the International Optic Nerve Trauma Study[J]. Ophthalmology, 1999, 106(7): 1268－1277.
|
| [7] |
Edwards P, Arango M, Balica L, et al.CRASH trial collaborators. Final results of MRC CRASH, a randomised placebo－controlled trial of intravenous corticosteroid in adults with head injury－outcomes at 6 months[J]. Lancet, 2005, 365(9475): 1957－1959.
|
| [8] |
Ben Simon GJ, Hovda DA, Harris NG, et al. Traumatic brain injury induced neuroprotection of retinal ganglion cells to optic nerve crush[J]. J Neurotrauma, 2006, 23(7): 1072－1082.
|
| [9] |
Huang TL, Chang CH, Lin KH, et al. Lack of protective effect of local administration of triamcinolone or systemic treatment with methylprednisolone against damages caused by optic nerve crush in rats[J]. Exp Eye Res, 2011, 92(2): 112－119.
|
| [10] |
Steinsapir KD, Goldberg RA, Sinha S, et al. Methylprednisolone exacerbates axonal loss following optic nerve trauma in rats[J]. Restor Neurol Neurosci, 2000, 17(4): 157－163.
|
| [11] |
Wei W, Zhao SF, Li Y, et al. The outcome of surgical and non－surgical treatments for traumatic optic neuropathy: a comparative study of 685 cases[J]. Ann Transl Med, 2022, 10(10): 542.
|
| [12] |
Mabuchi F, Aihara M, Mackey MR, et al. Optic nerve damage in experimental mouse ocular hypertension[J]. Invest Ophthalmol Vis Sci, 2003, 44(10): 4321－4330.
|
| [13] |
Yan W, Lin J, Hu W, et al. Combination analysis on the impact of the initial vision and surgical time for the prognosis of indirect traumatic optic neuropathy after endoscopic transnasal optic canal decompression[J]. Neurosurg Rev, 2021, 44(2): 945－952.
|
| [14] |
Xu R, Chen F, Zuo K, et al. Endoscopic optic nerve decompression for patients with traumatic optic neuropathy: is nerve sheath incision necessary？[J]. ORL J Otorhinolaryngol Relat Spec, 2014, 76(1): 44－49.
|
| [15] |
Yu B, Ma YJ, Tu YH, et al. Newly onset indirect traumatic optic neuropathy－surgical treatment first versus steroid treatment first[J]. Int J Ophthalmol, 2020, 13(1): 124－128.
|
| [16] |
Kimáková P, Solár P, Solárová Z, et al. Erythropoietin and Its Angiogenic Activity[J]. Int J Mol Sci, 2017, 18(7): 1519.
|
| [17] |
Ostrowski D, Heinrich R. Alternative Erythropoietin Receptors in the Nervous System[J]. J Clin Med, 2018, 7(2): 24.
|
| [18] |
Klopsch C, Skorska A, Ludwig M, et al. Intramyocardial angiogenetic stem cells and epicardial erythropoietin save the acute ischemic heart[J]. Dis Model Mech, 2018, 11(6): 033282.
|
| [19] |
Hemani S, Lane O, Agarwal S, et al. Systematic Review of Erythropoietin (EPO) for Neuroprotection in Human Studies[J]. Neurochem Res, 2021, 46(4): 732－739.
|
| [20] |
García－Ramírez M, Hernández C, Simó R. Expression of erythropoietin and its receptor in the human retina: a comparative study of diabetic and nondiabetic subjects[J]. Diabetes Care, 2008, 31(6): 1189－1194.
|
| [21] |
Dreixler JC, Hagevik S, Hemmert JW, et al. Involvement of erythropoietin in retinal ischemic preconditioning[J]. Anesthesiology, 2009, 110(4): 774－780.
|
| [22] |
Wang Y, Zhang H, Liu Y, et al. Erythropoietin (EPO) protects against high glucose－induced apoptosis in retinal ganglional cells[J]. Cell Biochem Biophys, 2015, 71(2): 749－755.
|
| [23] |
Shen J, Wu Y, Xu JY, et al. ERK－ and Akt－dependent neuroprotection by erythropoietin (EPO) against glyoxal－AGEs via modulation of Bcl－xL, Bax, and BAD[J]. Invest Ophthalmol Vis Sci, 2010, 51(1): 35－46.
|
| [24] |
Kilic U, Kilic E, Soliz J, et al. Erythropoietin protects from axotomy－induced degeneration of retinal ganglion cells by activating ERK－1/－2[J]. FASEB J, 2005, 19(2): 249－251.
|
| [25] |
Chong ZZ, Kang JQ, Maiese K. Erythropoietin fosters both intrinsic and extrinsic neuronal protection through modulation of microglia, Akt1, Bad, and caspase－mediated pathways[J]. Br J Pharmacol, 2003, 138(6): 1107－1118.
|
| [26] |
Ma R, Hu J, Huang C, et al. JAK2/STAT5/Bcl－xL signalling is essential for erythropoietin－mediated protection against apoptosis induced in PC12 cells by the amyloid β－peptide Aβ25－35[J]. Br J Pharmacol, 2014, 171(13): 3234－3245.
|
| [27] |
Villa P, Bigini P, Mennini T, et al. Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis[J]. J Exp Med, 2003, 198(6): 971－975.
|
| [28] |
Bond WS, Rex TS. Evidence That Erythropoietin Modulates Neuroinflammation through Differential Action on Neurons, Astrocytes, and Microglia[J]. Front Immunol, 2014, 5：523.
|
| [29] |
Wang H, Fan J, Chen M, et al. rhEPO Enhances Cellular Anti－oxidant Capacity to Protect Long－Term Cultured Aging Primary Nerve Cells[J]. J Mol Neurosci, 2017, 62(3－4): 291－303.
|
| [30] |
Guix FX, Uribesalgo I, Coma M, Mu？oz FJ. The physiology and pathophysiology of nitric oxide in the brain[J]. Prog Neurobiol, 2005, 76(2): 126－52.
|
| [31] |
Kawakami M, Sekiguchi M, Sato K, et al. Erythropoietin receptor－mediated inhibition of exocytotic glutamate release confers neuroprotection during chemical ischemia[J]. J Biol Chem, 2001, 276(42): 39469－39475.
|
| [32] |
Kretz A, Happold CJ, Marticke JK, et al. Erythropoietin promotes regeneration of adult CNS neurons via Jak2/Stat3 and PI3K/AKT pathway activation[J]．Mol Cell Neurosci, 2005, 29(4): 569－579.
|
| [33] |
Dubreuil CI, Winton MJ, McKerracher L. Rho activation patterns after spinal cord injury and the role of activated Rho in apoptosis in the central nervous system[J]. J Cell Biol, 2003, 162(2): 233－243.
|
| [34] |
Tan H, Zhong Y, Shen X, et al. Erythropoietin promotes axonal regeneration after optic nerve crush in vivo by inhibition of RhoA/ROCK signaling pathway[J]. Neuropharmacology, 2012, 63(6): 1182－1190.
|
| [35] |
King CE, Rodger J, Bartlett C, et al. Erythropoietin is both neuroprotective and neuroregenerative following optic nerve transection[J]. Exp Neurol, 2007, 205(1): 48－55.
|
| [36] |
Rex TS, Wong Y, Kodali K, et al. Neuroprotection of photoreceptors by direct delivery of erythropoietin to the retina of the retinal degeneration slow mouse[J]. Exp Eye Res, 2009, 89(5): 735－740.
|
| [37] |
Zhang JF, Wu YL, Xu JY, et al. Pharmacokinetic and toxicity study of intravitreal erythropoietin in rabbits[J]. Acta Pharmacol Sin, 2008, 29(11): 1383－90.
|
| [38] |
DeJulius CR, Bernardo－Colón A, Naguib S, et al. Microsphere antioxidant and sustained erythropoietin－R76E release functions cooperate to reduce traumatic optic neuropathy[J]. J Control Release, 2021, 329：762－773.
|
| [39] |
Kashkouli MB, Pakdel F, Sanjari MS, et al. Erythropoietin: a novel treatment for traumatic optic neuropathy－a pilot study[J]. Graefes Arch Clin Exp Ophthalmol, 2011, 249(5): 731－736.
|
| [40] |
Entezari M, Esmaeili M, Yaseri M. A pilot study of the effect of intravenous erythropoetin on improvement of visual function in patients with recent indirect traumatic optic neuropathy[J]. Graefes Arch Clin Exp Ophthalmol, 2014, 252(8): 1309－1313.
|
| [41] |
Kashkouli MB, Yousefi S, Nojomi M, et al. Traumatic optic neuropathy treatment trial (TONTT): open label, phase 3, multicenter, semi－experimental trial[J]. Graefes Arch Clin Exp Ophthalmol, 2018, 256(1): 209－218.
|
| [42] |
Rashad MA, Abdel Latif AAM, Mostafa HA, et al. Visual－Evoked－Response－Supported Outcome of Intravitreal Erythropoietin in Management of Indirect Traumatic Optic Neuropathy[J]. J Ophthalmol, 2018: 2750632.
|
| [43] |
King CE, Rodger J, Bartlett C, et al. Erythropoietin is both neuroprotective and neuroregenerative following optic nerve transection[J]. Exp Neurol. 2007, 205(1): 48－55.
|
| [44] |
VSong BJ, Cai H, Tsai JC, et al. Intravitreal recombinant human erythropoietin: a safety study in rabbits[J]. Curr Eye Res. 2008, 33(9): 750－760.
|
| [45] |
Zhang J, Wu Y, Jin Y, et al. Intravitreal injection of erythropoietin protects both retinal vascular and neuronal cells in early diabetes[J]. Invest Ophthalmol Vis Sci. 2008, 49(2): 732－742.
|
| [46] |
Modarres M, Falavarjani KG, Nazari H, et al. Intravitreal erythropoietin injection for the treatment of non－arteritic anterior ischaemic optic neuropathy[J]. Br J Ophthalmol. 2011, 95(7): 992－995.
|
| [47] |
Lagrèze WA, Feltgen N, Bach M, et al. Feasibility of intravitreal erythropoietin injections in humans[J]. Br J Ophthalmol. 2009, 93(12): 1667－1671.
|